Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity

Ophthalmology 2023;130:373-378 ª 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmolog

中文摘要

此研究比較了治療早產兒視網膜病變的兩種靜脈內注射藥物，Bevacizumab和Ranibizumab，並探討不同劑量或類型的抗血管內皮生長因子(VEGF)是否與再次治療有關。研究收集了661名患者873只眼睛的數據。主要分析的樣本包括307名患者的567只眼睛，其中沒有再次治療和再次治療兩組在出生體重、胎齡、首次注射年齡、ROP階段或受影響的時鐘小時數等方面沒有差異。然而，再次治療組中，有較大比例的ROP較為激進aggressive(34%對18%)，並且有更大比例的第一區ROP(49對34%)。與此同時，Bevacizumab的較低劑量與較高的再次治療率相關。研究結果還發現，Ranibizumab的使用與較高的再次治療率相關，而Bevacizumab的較低劑量與再次治療相關。

English Abstract

This study compares the retreatments between Bevacizumab and Ranibizumab intravitreal injections in treating Retinopathy of Prematurity (ROP), examining if specific dosages or types of anti-vascular endothelial growth factors (VEGF) are associated with retreatment. Data from 873 eyes of 661 patients were collected. The primary analysis included 567 eyes of 307 patients, where no significant difference was found between the no retreatment and retreatment groups in terms of birthweight, gestational age, age at first injection, ROP stages, or number of involved clock hours. However, the retreatment group had a larger percentage of aggressive ROP (34% vs 18%) and a greater percentage of zone 1 ROP (49% vs 34%). Concurrently, lower doses of Bevacizumab were associated with higher retreatment rates. The results also found that the use of Ranibizumab was associated with a higher rate of retreatment, whereas the rate of retreatment was not associated with a specific dose of ranibizumab. In a multicenter study of ROP patients initially treated with anti-VEGF therapy, ranibizumab and
lower-dose bevacizumab use were associated with an increased rate of retreatment when compared with higher dose bevacizumab.